サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1402920

血友病治療薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Hemophilia Treatment Drugs Market (Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 188 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
血友病治療薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2023年11月28日
発行: Transparency Market Research
ページ情報: 英文 188 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

血友病治療薬市場 - レポートの範囲

世界の血友病治療薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標に関する貴重な洞察を得る機会を研究しています。このレポートは、世界の血友病治療薬の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。レポートは、2023年から2031年までの世界の血友病治療薬市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、血友病治療薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 118億米ドル
2031年の市場価値 186億米ドル
CAGR 5%

このレポートは、世界の血友病治療薬市場の競合情勢を詳しく掘り下げています。世界の血友病治療薬市場で活動する主要企業が特定され、それぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の血友病治療薬市場のプレーヤーの属性です。

目次

第1章 エグゼクティブサマリー

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • 市場セグメンテーション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2023年～2031年

第5章 重要な洞察

  • パイプライン分析
  • 種類一覧
  • 主要国の世界の病気の有病率と罹患率
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：製品別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製品別、2023年～2031年
    • 組換え凝固因子濃縮物
      • 第VIII因子
      • 第IX因子
      • その他
    • 血漿由来凝固因子濃縮物
      • 第VIII因子
      • 第IX因子
      • その他
    • その他
  • 市場の魅力度：製品別

第7章 世界市場の分析と予測：疾患適応別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患適応別、2023年～2031年
    • 血友病A
    • 血友病B
    • その他
  • 市場の魅力：疾患別

第8章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2023年～2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力：流通チャネル別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2023年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

  • 市場企業 - 競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Pfizer Inc.
    • CSL Behring
    • Kedrion
    • Takeda Pharmaceutical Company Limited
    • Novo Nordisk A/S
    • Bayer AG
    • F. Hoffmann-La Roche Ltd.
    • Octapharma AG
    • Biotest AG
    • Sanofi SA
図表

List of Tables

  • Table 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 2: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 3: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 4: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Region, 2023-2031
  • Table 5: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country, 2023-2031
  • Table 6: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 7: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 8: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 9: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 11: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 12: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
  • Table 13: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 15: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 16: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 17: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 19: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 20: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
  • Table 21: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 23: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 24: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031

List of Figures

  • Figure 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 2: Global Hemophilia Treatment Drugs Market Value Share, by Product, 2022
  • Figure 3: Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2022
  • Figure 4: Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 5: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 6: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 7: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 8: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 9: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 10: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 11: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 12: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 13: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 14: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 15: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 16: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 17: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 18: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 19: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 20: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 22: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 23: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 24: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 25: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 26: Europe America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 27: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 28: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 29: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 30: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 31: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 32: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 35: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 36: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 37: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 38: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 39: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 40: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 41: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 44: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 45: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 46: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 47: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 48: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 49: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 50: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 51: Middle East & Africa America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2023-2031
  • Figure 52: Middle East & Africa America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 53: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 54: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 55: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2022)
目次
Product Code: TMRGL1900

Hemophilia Treatment Drugs Market - Scope of Report

TMR's report on the global hemophilia treatment drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global hemophilia treatment drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hemophilia treatment drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hemophilia treatment drugs market.

Market Snapshot
Market Value in 2023US$ 11.8 Bn
Market Value in 2031US$ 18.6 Bn
CAGR5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hemophilia treatment drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hemophilia treatment drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hemophilia treatment drugs market.

The report delves into the competitive landscape of the global hemophilia treatment drugs market. Key players operating in the global hemophilia treatment drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hemophilia treatment drugs market profiled in this report.

Key Questions Answered in Global hemophilia treatment drugs Market Report:

  • What is the sales/revenue generated by hemophilia treatment drugs across all regions during the forecast period?
  • What are the opportunities in the global hemophilia treatment drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Hemophilia Treatment Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global hemophilia treatment drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hemophilia treatment drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hemophilia treatment drugs market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemophilia Treatment Drugs Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. List of Types of Hemophilia Treatment Drugs
  • 5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product, 2023-2031
    • 6.3.1. Recombinant Coagulation Factor Concentrates
      • 6.3.1.1. Factor VIII
      • 6.3.1.2. Factor IX
      • 6.3.1.3. Others
    • 6.3.2. Plasma-derived Coagulation Factor Concentrates
      • 6.3.2.1. Factor VIII
      • 6.3.2.2. Factor IX
      • 6.3.2.3. Others
    • 6.3.3. Others
  • 6.4. Market Attractiveness, by Product

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 7.3.1. Hemophilia A
    • 7.3.2. Hemophilia B
    • 7.3.3. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2023-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness, by Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product, 2023-2031
    • 10.2.1. Recombinant Coagulation Factor Concentrates
      • 10.2.1.1. Factor VIII
      • 10.2.1.2. Factor IX
      • 10.2.1.3. Others
    • 10.2.2. Plasma-derived Coagulation Factor Concentrates
      • 10.2.2.1. Factor VIII
      • 10.2.2.2. Factor IX
      • 10.2.2.3. Others
    • 10.2.3. Others
  • 10.3. Market Attractiveness, by Product
  • 10.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 10.4.1. Hemophilia A
    • 10.4.2. Hemophilia B
    • 10.4.3. Others
  • 10.5. Market Attractiveness, by Disease Indication
  • 10.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies
    • 10.6.3. Online Pharmacies
  • 10.7. Market Attractiveness, by Distribution Channel
  • 10.8. Market Value Forecast, by Country, 2023-2031
    • 10.8.1. U.S.
    • 10.8.2. Canada
  • 10.9. Market Attractiveness Analysis
    • 10.9.1. By Product
    • 10.9.2. By Disease Indication
    • 10.9.3. By Distribution Channel
    • 10.9.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Recombinant Coagulation Factor Concentrates
      • 11.1.2.1. Factor VIII
      • 11.1.2.2. Factor IX
      • 11.1.2.3. Others
    • 11.1.3. Plasma-derived Coagulation Factor Concentrates
      • 11.1.3.1. Factor VIII
      • 11.1.3.2. Factor IX
      • 11.1.3.3. Others
    • 11.1.4. Others
  • 11.2. Market Attractiveness, by Product
  • 11.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 11.3.1. Hemophilia A
    • 11.3.2. Hemophilia B
    • 11.3.3. Others
  • 11.4. Market Attractiveness, by Disease Indication
  • 11.5. Market Value Forecast, by Distribution Channel, 2023-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Attractiveness, by Distribution Channel
  • 11.7. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.7.1. Germany
    • 11.7.2. U.K.
    • 11.7.3. France
    • 11.7.4. Italy
    • 11.7.5. Spain
    • 11.7.6. Rest of Europe
  • 11.8. Market Attractiveness Analysis
    • 11.8.1. By Product
    • 11.8.2. By Disease Indication
    • 11.8.3. By Distribution Channel
    • 11.8.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2023-2031
    • 12.2.1. Recombinant Coagulation Factor Concentrates
      • 12.2.1.1. Factor VIII
      • 12.2.1.2. Factor IX
      • 12.2.1.3. Others
    • 12.2.2. Plasma-derived Coagulation Factor Concentrates
      • 12.2.2.1. Factor VIII
      • 12.2.2.2. Factor IX
      • 12.2.2.3. Others
    • 12.2.3. Others
  • 12.3. Market Attractiveness, by Product
  • 12.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 12.4.1. Hemophilia A
    • 12.4.2. Hemophilia B
    • 12.4.3. Others
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Online Pharmacies
  • 12.7. Market Attractiveness, by Distribution Channel
  • 12.8. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.8.1. China
    • 12.8.2. Japan
    • 12.8.3. India
    • 12.8.4. Australia & New Zealand
    • 12.8.5. Rest of Asia Pacific
  • 12.9. Market Attractiveness Analysis
    • 12.9.1. By Product
    • 12.9.2. By Disease Indication
    • 12.9.3. By Distribution Channel
    • 12.9.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2023-2031
    • 13.2.1. Recombinant Coagulation Factor Concentrates
      • 13.2.1.1. Factor VIII
      • 13.2.1.2. Factor IX
      • 13.2.1.3. Others
    • 13.2.2. Plasma-derived Coagulation Factor Concentrates
      • 13.2.2.1. Factor VIII
      • 13.2.2.2. Factor IX
      • 13.2.2.3. Others
    • 13.2.3. Others
  • 13.3. Market Attractiveness, by Product
  • 13.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 13.4.1. Hemophilia A
    • 13.4.2. Hemophilia B
    • 13.4.3. Others
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Online Pharmacies
  • 13.7. Market Attractiveness, by Distribution Channel
  • 13.8. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.8.1. Brazil
    • 13.8.2. Mexico
    • 13.8.3. Rest of Latin America
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Product
    • 13.9.2. By Disease Indication
    • 13.9.3. By Distribution Channel
    • 13.9.4. By Country/Sub-region

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2023-2031
    • 14.2.1. Recombinant Coagulation Factor Concentrates
      • 14.2.1.1. Factor VIII
      • 14.2.1.2. Factor IX
      • 14.2.1.3. Others
    • 14.2.2. Plasma-derived Coagulation Factor Concentrates
      • 14.2.2.1. Factor VIII
      • 14.2.2.2. Factor IX
      • 14.2.2.3. Others
    • 14.2.3. Others
  • 14.3. Market Attractiveness, by Product
  • 14.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 14.4.1. Hemophilia A
    • 14.4.2. Hemophilia B
    • 14.4.3. Others
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Online Pharmacies
  • 14.7. Market Attractiveness, by Distribution Channel
  • 14.8. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 14.8.1. GCC Countries
    • 14.8.2. South Africa
    • 14.8.3. Rest of Middle East & Africa
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Product
    • 14.9.2. By Disease Indication
    • 14.9.3. By Distribution Channel
    • 14.9.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. CSL Behring
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Kedrion
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Takeda Pharmaceutical Company Limited
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Novo Nordisk A/S
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Bayer AG
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann-La Roche Ltd.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Octapharma AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Biotest AG
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Sanofi S.A.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview